Comparing two drug combos for relapsed multiple myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial looks at two different drug combinations given before a second stem cell transplant for multiple myeloma that has come back after first treatment. It aims to see if adding two extra drugs (bortezomib and bendamustine) to the standard drug (melphalan) works better than using the standard drug alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have multiple myeloma that came back after your first stem cell transplant.
- You are scheduled to have a second stem cell transplant as part of your second line of treatment.
- You will receive either a combination of three drugs (bortezomib, bendamustine, and melphalan) or just melphalan before your second transplant.
- You did not receive two back-to-back stem cell transplants in a row (tandem transplant) for your first or second treatment.
- You did not receive a donor (allogeneic) stem cell transplant as part of your first or second treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at two different drug combinations for people with multiple myeloma who are eligible for a stem cell transplant. It aims to find which treatment works better.
This trial compares two different combinations of medications for people with newly diagnosed multiple myeloma who are not planning to have a stem cell transplant. It looks at whether adding a targeted antibody drug is as effective as the standard approach.
This trial tests whether a new drug called elranatamab combined with lenalidomide works better than the standard daratumumab/lenalidomide combination as maintenance therapy after a stem cell transplant for newly diagnosed myeloma.
This trial tests two different combinations of medicines in people who still have signs of multiple myeloma after a stem cell transplant. One group gets teclistamab and talquetamab, and the other gets daratumumab and lenalidomide. The goal is to see which works better at removing any remaining cancer cells.
This trial tests a combination of two antibody drugs (elotuzumab and daratumumab) plus an oral pill (iberdomide) and a steroid (dexamethasone) for people whose multiple myeloma has come back after treatment. The goal is to see if this new mix works better than what's already available.
This study tests a new combination of two drugs, teclistamab and pomalidomide, against the usual treatment of three drugs for multiple myeloma that has come back shortly after a standard treatment. The goal is to see if the new combination works better or is safer.
Hear when a new Myeloma Multiple trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.